Genmab A/S
Bear Case (25th pct.)
-42.2% vs price
Base Case (Median)
-24.8% vs price
Bull Case (75th pct.)
-14.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $18.15 | -44.7% | High (40%) |
| PE Comparable | $28.26 | -13.9% | Medium (25%) |
| Graham Number | $16.38 | -50.1% | Medium (40%) |
| EV/EBITDA | $21.51 | -34.5% | Medium (20%) |
| EV/FCF | $27.91 | -15.0% | Medium (20%) |
| Earnings Power Value | $136.05 | 314.3% | Medium (50%) |
Based on 6 out of 8 methods, GMAB appears overvalued at the current price of $32.84. The base case fair value of $24.71 implies 24.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.